Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of Aaron's, Inc. (AAN)
March 31, 2020 15:17 ET
|
Glancy Prongay & Murray LLP; Aaron’s, Inc.
LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 28, 2020 deadline to file a lead plaintiff motion in the class action...
Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
May 07, 2019 07:30 ET
|
Biogen Inc.
Updated results support lower risk of PML with extended interval dosing (EID; approximately every six weeks) for TYSABRI® (natalizumab) in patients in a real-world setting New interim data further...
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
May 07, 2019 07:00 ET
|
uniQure Inc.
~ Data Show AMT-150 Able to Significantly Lower Mutant Ataxin-3 Protein in SCA3 Disease Model ~ ~ Provides Further Support of Proof-of-concept of Company’s Proprietary miQURE™ Gene Silencing...
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
May 06, 2019 12:57 ET
|
Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
May 01, 2019 16:30 ET
|
Biogen Inc.
Tofersen, an antisense oligonucleotide (ASO) that selectively targets the genetic driver of disease, is being studied for the potential treatment of ALS in adults with a confirmed superoxide dismutase...
Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
March 28, 2018 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that it has been selected for an Emerging Science dual oral...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aaron’s, Inc. – AAN
July 28, 2017 21:19 ET
|
The Rosen Law Firm PA
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aaron’s,...
MDA, AAN and ABF Award Clinical Research Training Fellowship for Muscular Dystrophy
July 14, 2017 11:04 ET
|
Muscular Dystrophy Association
Chicago, IL, July 14, 2017 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), together with the American Academy of Neurology (AAN) and the American Brain Foundation (ABF), is pleased to...
Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease
April 24, 2017 09:06 ET
|
Adamas Pharmaceuticals, Inc.
-- Results presented in oral platform and poster sessions at the 69th American Academy of Neurology (AAN) Annual Meeting -- -- Results from the pooled analysis showed approximately twice as many...
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
April 24, 2017 08:00 ET
|
aTyr Pharma Inc.
- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B...